Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

98.65
-0.3500-0.35%
Post-market: 98.650.00000.00%19:30 EDT
Volume:663.75K
Turnover:65.34M
Market Cap:1.60B
PE:9.19
High:99.48
Open:99.33
Low:98.25
Close:99.00
52wk High:108.66
52wk Low:72.94
Shares:16.25M
Float Shares:16.25M
Volume Ratio:4.65
T/O Rate:4.08%
Dividend:1.44
Dividend Rate:1.46%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

TIPRANKS
·
Sep 27

Ifinatamab Deruxtecan Biologics License Application for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Reuters
·
Sep 26

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Merck, Daiichi Sankyo Withdraw US Application for Lung Cancer Drug

Reuters
·
Sep 26

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan

TIPRANKS
·
Sep 26

Merck & Co - Daiichi Sankyo and Merck Withdraw Bla for Ifinatamab Deruxtecan in Es-Sclc in U.S.

THOMSON REUTERS
·
Sep 26

Merck & Co - Withdrawal Based on FDA Discussions; Phase 2 Data Do not Satisfy Approval Requirements

THOMSON REUTERS
·
Sep 26

Merck & Co - Patient Enrollment Continues in Ideate-Lung02 Phase 3 Trial for Ifinatamab Deruxtecan

THOMSON REUTERS
·
Sep 26

Merck & Co - Two Additional Phase 3 Trials Underway for Ifinatamab Deruxtecan in Crpc and Escc

THOMSON REUTERS
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.

Dow Jones
·
Sep 25

Bristol-Myers Squibb Says Zenbexus Combination Doubles MRD-Negative Complete Response in Multiple Myeloma Trial

MT Newswires Live
·
Sep 25

Bristol Myers reports results from prespecified analysis of EXCALIBER-RRMM trial

TIPRANKS
·
Sep 25

Bristol Myers Squibb Wins FDA Accelerated Approval for Zenbexus Combo in Multiple Myeloma

Reuters
·
Sep 25

Bristol Myers Squibb Announces First Presentation of Results for Zenbexus™ (Iberdomide) in Combination with Daratumumab from Phase 3 Excaliber-Rrmm Trial in Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 25

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25
More